SOUTH SAN FRANCISCO, Calif., March 23 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that Donald J. Santel, Chief Executive Officer, will provide a company overview at two upcoming investor conferences. A live transmission of the presentations will be available through the CoTherix website. The following is the schedule of presentations:
* Thursday, March 30, 2006, 11:00 a.m. EST, BioCentury Future Leaders Conference * Tuesday, April 4, 2006, 1:45 p.m. EDT, CIBC Biotechnology & Specialty Pharmaceuticals Conference
To access the live webcast, please go to www.cotherix.com and click on the “Investor Relations” link. There will be a replay available for approximately one week following the presentation.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix’s Ventavis(R) (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms (World Health Organization Group I). PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com
CoTherix, Inc.
CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551
